Arrhythmias & electrophysiology
Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology
Scope
As issued by the authors
Established and emerging indications for DOAC therapy in primary and secondary prevention of thrombotic events: AF, acute and extended VTE treatment, special populations (CKD, liver dysfunction, cancer, obesity, frailty, prior bleeding, valvular heart disease), periprocedural anticoagulation, antithrombotic strategies after stroke, left atrial appendage closure and catheter ablation; drug selection, dosing, duration, bleeding risk and management, drug-drug interactions, adherence, cost barriers
Original publication
Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. Published 30 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →